SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias sharp selloff is being tied by traders to fears that a Democratic sweep could bring tighter AI regulation or delay data-center projects, alongside broader doubts about AI spending and the sustainability of the chip rally. The community is divided between calling it an AI-bubble unwind and buying the dip on confidence in Nvidias long-term business.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp broad-market selloff is being tied by traders to fears that the Democrats midterm gains could bring tighter AI rules and slow data-center investment, adding pressure to tech-heavy indexes. The community is split between seeing the drop as an overreaction and buying opportunity and expecting further losses amid uncertainty and an unwind in AI-related stocks.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQs sharp tech-led selloff is being tied by traders to fears that the Democratic midterm sweep could bring tighter AI and data-center rules and slow infrastructure spending, with semiconductor weakness adding pressure. The community is split between seeing a deeper correction and AI-trade unwind ahead and viewing the drop as an overreaction or dip-buying opportunity.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Microns sharp selloff is being tied by traders to fears that Democratic gains and calls for tighter AI regulation could slow data-center construction and weaken demand for AI-related chips and memory, amid a broader semiconductor and AI-trade unwind. The community is divided between viewing the drop as an overreaction and dip-buying opportunity because AI memory demand remains strong, and warning that weaker AI spending or a prolonged sector reset could bring further declines.

Iovance Biotherapeutics, Inc. engages in the development and commercialization of cell therapies using autologous tumor-infiltrating lymphocytes (TIL) for the treatment of cancer. Its products include Amtagvi (lifileucel), and Proleukin (aldesleukin). The firm also develops investigational TIL therapies for other solid tumor cancers. The company was founded by Robert T. Brooke on September 17, 2007 and is headquartered in San Carlos, CA.

Iovance Biotherapeutics Inc

Iovances quarterly results drew attention with record revenue growth, improved gross margins, and a longer cash runway, but the stock sold off despite the strong report. Traders debate whether broad biotech-market weakness and profit-taking drove the decline or whether concerns about Amtagvis sequential growth and the lung-cancer programs durability and 2027 filing timeline are weighing on sentiment.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

A sharp semiconductor and AI-stock selloff has drawn attention to AMD, with traders speculating that post-midterm calls for AI regulation could slow data-center construction, alongside broader concerns about AI spending. The drop contrasts with AMDs strong results and outlook; some traders call it an overreaction and buying opportunity, while others see lingering capex and valuation risks.

Applied Optoelectronics, Inc. engages in the design and manufacture of optical communications products. Its products include optical devices, such as laser diodes, photodiodes, related modules and circuitry, and equipment for applications in fiber-to-the-home, cable television, point to point communications, and wireless. The company was founded by Chih Hsiang Lin on February 28, 1997 and is headquartered in Sugar Land, TX.

Applied Optoelectronics Inc

AAOI is drawing attention after a sharp selloff alongside AI and optical-infrastructure stocks, with traders citing concerns about hyperscaler spending, AI valuations and the companys upcoming earnings outlook. Some see the decline as an oversold buying opportunity, while others fear more downside and question whether strong results would be enough to reverse the weak sentiment.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unitys quarterly results and outlookfeaturing its first GAAP profit since going public, accelerating Vector advertising growth, and upbeat forward guidanceare driving the rally. Traders are largely celebrating a potential turnaround, while some question whether shares can sustain gains and break through resistance.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff has hammered SOXL, with traders pointing to fears that political shifts could constrain AI and data-center investment, alongside broader worries that the AI trade is unwinding. The funds 3x daily leverage has magnified the drop; traders disagree on whether it marks capitulation and a buying opportunity or further downside ahead.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

SMH is under pressure as semiconductor traders reassess the AI buildout, weighing concerns that data-center restrictions and doubts about returns on heavy AI spending could slow chip demand. The community is split between fears that the AI trade is unraveling and calls that the selloff is an overreaction, with compute demand still intact.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

MediWound (MDWD) Moves 6.1% Higher: Will This Strength Last?

MediWound (MDWD) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Korro Bio, Inc. (KRRO) Surges 29.7%: Is This an Indication of Further Gains?

Korro Bio, Inc. (KRRO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

All You Need to Know About Korro Bio, Inc. (KRRO) Rating Upgrade to Buy

Korro Bio, Inc. (KRRO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Strength Seen in Ono Pharmaceutical Co. (OPHLF): Can Its 9.2% Jump Turn into More Strength?

Ono Pharmaceutical Co. (OPHLF) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Korro Bio, Inc. (KRRO) Upgraded to Buy: What Does It Mean for the Stock?

Korro Bio, Inc. (KRRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?

Korro Bio, Inc. (KRRO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Korro Bio (KRRO) to Release Quarterly Earnings on Wednesday

Korro Bio (NASDAQ:KRRO) will be releasing its Q1 2026 earnings before the market opens on Wednesday, May 6. (View Earnings Report at...

What Makes Korro Bio, Inc. (KRRO) a New Buy Stock

Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of "Moderate Buy" from Analysts

Shares of Korro Bio, Inc. (NASDAQ:KRRO - Get Free Report) have earned an average rating of "Moderate Buy" from the eleven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, five hav...

Korro Bio (NASDAQ:KRRO) Stock Price Down 0.8%  - Should You Sell?

Korro Bio (NASDAQ:KRRO) Stock Price Down 0.8% - Here's Why...

Korro Bio, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the discovery, development, and commercialization of a new class of genetic medicines based on editing RNA. The company was founded by Nessan Bermingham, Jean-Francois B. Formela, Joshua Rosenthal, and Andrew Fraley in 2018 and is headquartered in Cambridge, MA.

Korro Bio Inc.

KRRO Shares Jump 13% On Analyst Upgrades — What’s Driving The Optimism?

Equity

Neutral Sentiment

<ul class="summary-bullets"><li>H.C. Wainwright said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."</li><li>Piper Sandler said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success.</li><li>Oppenheimer upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target.</li></ul>Shares of Korro Bio Inc. (KRRO) jumped 13% on Thursday after multiple analysts upgraded the stock on optimism about the company’s new development candidate KRRO-121.Korro is now looking to study the drug in the treatment of hyperammonemia. The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for the candidate.<h2 class="st-heading-2">Analysts Chime In</h2>H.C. Wainwright upgraded Korro Bio to ‘Buy’ from ‘Neutral’ with a $20 price target, according to TheFly. The firm said KRRO-121 adds a second, "independently risk-mitigated asset as a call option."Korro shares are trading near a zero enterprise value, the analyst told investors in a research note. H.C. Wainwright believes KRRO-121 is not a read-through from KRRO-110,"so this is a truly independent shot on goal."Piper Sandler analyst Yasmeen Rahimi on Wednesday also upgraded Korro Bio to ‘Overweight’ from ‘Neutral’ with a price target of $30, up from $11. Piper said it left the company’s analyst day on Tuesday with "strong conviction" for KRRO-121's probability of success, it said.The firm is bullish ahead of KRRO-121's new drug filing in the second half of 2026, saying there is a "clear precedence for a regulatory path."Oppenheimer also upgraded Korro Bio to ‘Outperform’ from ‘Perform’ with a $22 price target. The firm believes the company's probability of success is now reset and that KRRO-121 offers a fresh, interesting story wherein RNA editing can thrive. The firm sees potential for significant upside.<h2 class="st-heading-2">Pivot From KRRO-110</h2>In November, Korro said that in its <a href="https://stocktwits.com/news-articles/markets/equity/korro-bio-stock-crashes-over-75-after-hours-on-drug-failure-downgrades-and-layoffs/cLPBNsbREdA">trial</a> evaluating KRRO-110 in the genetic disorder called Alpha-1 Antitrypsin Deficiency (AATD), it achieved functional protein production with a single administration, but it did not achieve the protein levels projected based on preclinical data.The lower-than-expected results prompted a 34% reduction in working and the company subsequently opted KRRO-121 as its next development candidate, for the potential treatment of patients with hyperammonemia.Hyperammonemia is a critical metabolic condition defined by abnormally elevated blood ammonia levels, commonly resulting from liver failure (cirrhosis) or inherited urea cycle disorders. It causes acute, severe neurological impairment—including encephalopathy, seizures, coma, and cerebral edema—and requires immediate medical intervention to prevent fatal brain damage.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around KRRO stock rose from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume increased from ‘high’ to ‘extremely high’ levels.A Stocktwits user said that a strong momentum setup is shaping up, adding that buyers are defending these levels and pushing higher.<stembedurl>https://www.stocktwits.com/topstockalerts/message/643304339</stembedurl><a href="https://stocktwits.com/symbol/KRRO">KRRO shares</a> have dropped 60% in the past 12 months.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/trump-administration-reportedly-ready-to-lay-out-crypto-law/cmyikhjR41I">Trump Administration Reportedly Ready To Lay Out Crypto Rules</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

The company said on Tuesday that it intends to file an application in the second half of 2026 to begin its first in-human trial for its new development candidate KRRO-121. 

Current Price	$13.67
Prev Close	$16.62
Open	$15.72
Dividend Yield	0.00%
50-Day Moving Average	$11.57
Beta	2.59
Avg. Volume	199,928.49
PE Ratio	-1.66

52-Week High	$36.79
52-Week Low	$5.20
Market Capitalization	$244.74M
EPS (Annual)	-$12.48
Price to Book	2.37
Revenue Per Employee	$110,206.90

Feed

News

Sentiment

Earnings

Fundamentals

Info

KRRO Fundamentals